ArticleDermatopathology (Basel, Switzerland)2023
Histopathological Diagnosis of Malignant Melanoma at the Dawn of 2023: Knowledge Gained and New Challenges.
Article in Dermatopathology (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Disseminated Melanoma With Rare Multiorgan Visceral Involvement in a Young Adult: A Case Report.Clinical case reports · 2026Article
- From dermatopathology to the courtroom-The promise of cutaneous molecular biomarkers.Frontiers in medicine · 2026Article
- From Slide to Insight: The Emerging Alliance of Digital Pathology and AI in Melanoma Diagnostics.Cancers · 2025Review
- Metabolic Heterogeneity Confers Differences in the Tumor Microenvironment of Aggressive Types of Melanomas.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2025Article
- Advancements in Diagnosis of Neoplastic and Inflammatory Skin Diseases: Old and Emerging Approaches.Diagnostics (Basel, Switzerland) · 2025Review
- Quercetin as a Potential Therapeutic Agent for Malignant Melanoma-A Review of Current Evidence and Future Directions.Medicina (Kaunas, Lithuania) · 2025Review
- Wearable battery-free chip-less patch for bioimpedance measurement of cutaneous lesions.npj biomedical innovations · 2025Article
- Targeting TAMs & CAFs in melanoma: New approaches to tumor microenvironment therapy.Oncology research · 2025Review
- Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials.Cells · 2024Review
- Article
- Differences and Similarities in Epidemiology and Risk Factors for Cutaneous and Uveal Melanoma.Medicina (Kaunas, Lithuania) · 2023Review
- Low-molecular-weight fucoidan inhibits the proliferation of melanoma via Bcl-2 phosphorylation and PTEN/AKT pathway.Oncology research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Year after year, the incidence and prevalence rates of cutaneous Malignant Melanoma (MM) show a continuous increase and, according to the most up-to-date American Cancer Society (ACS) projections, it is estimated that 97,610 new melanomas will be diagnosed in 2023 (about 58,120 in men and 39,490 in women) and approximately 7990 people are expected to die of melanoma (about 5420 men and 2570 women) [...].
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.